Abstract
Objective The aim of this study is to systematically evaluate the efficacy and safety between dienogest and some GnRH-a while treating endometriosis.
Methods The search was applied to Cochrane Library, EMBASE, PubMed, Web of Science, CNKI, WANFANG DATA, VIP and CBM database. All types of clinical study about dienogest and GnRH-a in endometriosis were included. All authors extracted data and assessed literature quality independently. Meta-analysis was conducted using RevM an software.
Results Six studies included show that the efficiency of prevent uteruspain MD = 1.40(95% CI = 2.14–4.94, P = 4.94), the incidence of headache (OR = 0.75, 95%CI = 0.75–1.10, P = 0.14), and dienogest treatment of endometriosis in the possibility of hot flashes (OR = 0.18, 95% CI = 0.18–0.27, P < 0.00001) and the possibility of weight gain (OR = 0.74, 95% CI = 0.74–1.29, P = 0.29) than GnRH-a group of small, in contrast, use dienogest in the treatment of endometriosis with irregular bleeding possibility is larger than GnRH-a group (OR = 15.83, 95% CI = 15.83–30.82,P < 0.00001).
Conclusion Compared the prevent uteruspain in treating endometriosis, dienogest and GnRH-a perform an analogous effect in prevent pain. But both could cause different degree of adverse reactions. Clinical medication should be depending upon the patients’ and clinical condition.
Keywords
References
Clark HD, Wells GA, Huët C, McAlister FA, Salmi LR, Fergusson D, et al. Assessing the quality of randomized trials: Reliability of the Jadad Scale. Control Clin Trials. 1999;20:448–452.
Palmer MK. WHO Handbook for Reporting Results of Cancer Treatment; World Health Organization: Geneva, Switzerland, 1979; Vol. 38, pp. 484–485.
Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: A 24-week, randomized, multicentre, open-label trial. Human Reprod. 2010;25:633–641.
Gerlinger C, Faustmann T, Hassall JJ, Seitz C. Treatment of endometriosis in different ethnic populations: A meta-analysis of two clinical trials. BMC Womens Health. 2012;12:9.
Takaesu Y, Nishi H, Kojima J, Sasaki T, Nagamitsu Y, Kato R, et al. Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis. J Obstet Gynaecol Res. 2016;42:1152–1158.
Vercellini P, Trespidi L, Colombo A, Vendola N, Marchini M, Crosignani PG. Gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril. 1993;60:75–79.
Vercellini P, Bracco B, Mosconi P, Roberto A, Alberico D, Dhouha D, et al. Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: A before and after study. Fertil Steril. 2016;105:734–743.
Harada T, Taniguchi F. Dienogest: A new therapeutic agent for the treatment of endometriosis. Womens Health. 2010;6:27–35.
Kitawaki J, Kusuki I, Yamanaka K, Suganuma I. Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain. Eur J Obstet Gynecol Reprod Biol. 2011;157:212–216.
Ichigo S, Takagi H, Matsunami K, Suzuki N, Imai A. Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist. Arch Gynecol Obstet. 2011;284:667–670.
Andres Mde P, Lopes LA, Baracat EC, Podgaec S. Dienogest in the treatment of endometriosis: Systematic review. Arch Gynecol Obstet. 2015;292:523–529.
Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. Int J Gynecol Obstet. 2012;117:228–233.
Refbacks
- There are currently no refbacks.
Copyright (c) 2018 Journal of Pharmaceutical and Biomedical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.